Conference Coverage

Cultural humility required to optimize treatment of eczema patients with skin of color


 

AT SPD 2022

Follicular, nummular eczema

In her clinical experience, the most common clinical variants of AD in patients with skin of color is follicular eczema. “Examine the patient, apply your hand to the affected area, and you can feel the papules beneath your fingertips,” she advised.

“That’s what I teach my residents and medical students,” she said. “If you are looking for erythema to seal your diagnosis of AD, it may not happen. You may see more of a violaceous hue and sometimes you may not find it at all, depending on the patient’s skin tone. If I find an area of normal appearing skin and then look back at the area of active skin disease, I go back and forth until I’m able to train my eye to be able to see those violaceous and erythematous hues more easily.”

Nummular eczema can also be a challenge in AD patients with skin of color.

“I like to listen to buzz words,” Dr. Heath said. “If a parent says, ‘my child has been diagnosed with ringworm multiple times,’ I zoom in on that. We know that kids can get tinea corporis, but usually not multiple times. I ask about all the things that can be associated with AD, and often we do see these nummular plaques on the skin and do some education about that. I also talk to their pediatrician or send information to that person so that they can be aware that nummular eczema is a form of AD.”

She noted that AD of the scalp may be confused with tinea capitis, especially in young Black children with moderate to severe AD. In her experience, triamcinolone 0.1% ointment works well for AD of the scalp.

She concluded her presentation by noting that there is no easy solution to treating AD in young patients with skin of color. “It’s way more than just eczema. We can help people see AD in a different way. My goal is to see the value in challenging ourselves to understand the impact of what happens outside of the exam room on these patients.”

Dr. Heath disclosed that she has served as a consultant for several pharmaceutical companies, including Regeneron, Janssen, Arcutis, Johnson and Johnson, Cassiopea, and Lilly.

Pages

Recommended Reading

Dupilumab under FDA review for atopic dermatitis in children aged 6 months to 5 years
MDedge Pediatrics
Managing overuse of food IgE panels: Multiple approaches needed
MDedge Pediatrics
Probiotic LGG doesn’t lessen eczema, asthma, or rhinitis risk by age 7
MDedge Pediatrics
Steroid phobia drives weaker prescribing, nonadherence for AD
MDedge Pediatrics
FDA approves dupilumab for children with eczema aged 6 months to 5 years
MDedge Pediatrics
Therapeutic patient education can help with adherence to treatment
MDedge Pediatrics
Atopic dermatitis: Options abound, and more are coming
MDedge Pediatrics
Introduce allergens early, say French allergists
MDedge Pediatrics
Antibiotics during pregnancy may increase child’s risk for asthma and other atopic diseases
MDedge Pediatrics
Eczema causes substantial burden for many infants and preschoolers
MDedge Pediatrics